Dapagliflozin in Patients With Critical Illness (DEFENDER)
Dapagliflozin in Patients With Critical Illness: A Randomized Controlled Trial
Sponsor: Hospital Israelita Albert Einstein
A PHASE3 clinical study on Critical Illness and Sepsis, this trial is completed. The trial is conducted by Hospital Israelita Albert Einstein and has accumulated 12 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hospital Israelita Albert Einstein
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aparecida de Goiânia, Brazil , Aracaju, Brazil , Arapiraca, Brazil , Barretos, Brazil , Brasília, Brazil , Colatina, Brazil , Curitiba, Brazil , Florianópolis, Brazil , Jales, Brazil , Joinville, Brazil and 7 more locations